Om

HJ Science Co., Ltd. is a clinical-stage biotechnology company based in Sichuan, China, founded in 2017. The company specializes in the research and development of innovative small-molecule drugs targeting autoimmune, metabolic, and oncology diseases. Its current portfolio is centered on three core product candidates: HJ787, a selective TYK2 inhibitor being developed in topical and oral forms for inflammatory skin conditions such as atopic dermatitis, psoriasis, neurodermatitis, and acne vulgaris; HJ178, an orally administered agent aimed at treating type 2 diabetes and related metabolic disorders; and HJ891, a KRAS-targeted therapy being developed in both oral and injectable forms for non-small-cell lung cancer. These programs position HJ Science within high-need therapeutic areas where demand for differentiated, targeted treatments supports partnerships with healthcare providers, research institutions, and the broader pharmaceutical ecosystem. Through its pipeline, the company plays a focused role in advancing China’s domestic innovative drug development for immune-mediated and cancer indications.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I HJ SCIENCE CO MED ENDAVU: Køb HJ Science Co ($6132) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i HJ Science Co, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.